Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ahah
- Development stage
- Phase 4
- Lead developer
- Nguyen Thi Trieu
- Administration
- Oral
01
Overview
**Ahah** is an investigational multi-herb botanical formulation containing concentrated extracts of *Adenosma glutinosum*, *Dioscorea cirrhosa*, *Eclipta prostrata*, *Impatiens balsamina*, and *Phyllanthus urinaria*, together with ascorbic acid. It was registered for evaluation in people with HIV-1 infection and AIDS, with the intended purpose of protecting or increasing CD4-positive T-lymphocyte and B-lymphocyte levels. No defined molecular target, antiviral mechanism, marketed status, or clinical efficacy has been established in the identified public trial record. ([ichgcp.net](https://ichgcp.net/fi/clinical-trials-registry/NCT04770701))
- Other names
- AhahAhah Drug
Beyond the preview
Go deeper on Ahah.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ahah.